Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback